Two patients treated with Zolgensma, a Novartis gene therapy for a rare inherited disorder, have died, highlighting a known but rare side effect risk associated with this and other genetic medicines. The children who died experienced acute liver failure at about five to six weeks following infusion with the gene therapy and within 10 days after the start of […]
